38,502 reports of this reaction
5.2% of all RITUXIMAB reports
#1 most reported adverse reaction
OFF LABEL USE is the #1 most commonly reported adverse reaction for RITUXIMAB, manufactured by Genentech, Inc.. There are 38,502 FDA adverse event reports linking RITUXIMAB to OFF LABEL USE. This represents approximately 5.2% of all 743,156 adverse event reports for this drug.
RITUXIMAB has an overall safety score of 85 out of 100. Patients taking RITUXIMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among RITUXIMAB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for RITUXIMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 38,502 FDA reports for RITUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 5.2% of all adverse event reports for RITUXIMAB, making it one of the most commonly reported side effect.
If you experience off label use while taking RITUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.